ViiV Healthcare, Halozyme partner to develop HIV medicines
ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV. The deal gives exclusive access to Halozyme’s ENHANZE drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.